218 related articles for article (PubMed ID: 33794909)
1. Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ; Mol BW; Longobardi S; Orvieto R; Venetis CA; Lispi M; Storr A; D'Hooghe T
Reprod Biol Endocrinol; 2021 Apr; 19(1):51. PubMed ID: 33794909
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
3. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
[TBL] [Abstract][Full Text] [Related]
5. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.
Gizzo S; Ferrando M; Lispi M; Ripellino C; Cataldo N; Bühler K
J Med Econ; 2018 Nov; 21(11):1096-1101. PubMed ID: 30113238
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?
de Mora F; Howles CM
Drug Discov Today; 2022 Aug; 27(8):2071-2075. PubMed ID: 35490965
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
10. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
12. XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.
Hoy SM
BioDrugs; 2016 Aug; 30(4):379-86. PubMed ID: 27342604
[TBL] [Abstract][Full Text] [Related]
13. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.
Patel NH; Patel NH; Patel MN; Bhadarka HK; Vyas KS
J Hum Reprod Sci; 2023; 16(2):148-155. PubMed ID: 37547084
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
Šprem Goldštajn M; Dumančić S; Mikuš M
J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
[TBL] [Abstract][Full Text] [Related]
16. Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.
Lehmann M; Arbo E; Pouly JL; Barrière P; Boland LA; Bean SG; Jenkins J
Eur J Obstet Gynecol Reprod Biol X; 2024 Jun; 22():100311. PubMed ID: 38741750
[TBL] [Abstract][Full Text] [Related]
17. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
18. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Schwarze JE; Venetis C; Iniesta S; Falla E; Lukyanov V; de Agustin Calvo E; D Hooghe T; Roeder C; Matorras R
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):203-216. PubMed ID: 35227619
[TBL] [Abstract][Full Text] [Related]
19. A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.
Bühler K; Naether OG; Bilger W
Reprod Biol Endocrinol; 2014 Jan; 12():6. PubMed ID: 24423045
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha.
Barakhoeva Z; Vovk L; Fetisova Y; Marilova N; Ovchinnikova M; Tischenko M; Scherbatyuk Y; Kolotovkina A; Miskun A; Kasyanova G; Teterina T; Zorina I; Belousova N; Morozova E; Yakovenko S; Apryshko V; Sichinava L; Shalinа R; Polzikov M
Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():6-12. PubMed ID: 31400644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
